Idorsia Ltd Idorsia Ltd

Idorsia Ltd

IDIA

Rank in Stocks #7690
Idorsia Ltd, a biopharmaceutical company, engages in the discovery,... Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The companyโ€™s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Share Price
$4.74
Last synced: 2026-11-12
Market Cap
$1.26B
Change (1 day)
-2.37%
Change (1 year)
19.13%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Category

Healthcare
EPS for Idorsia Ltd (IDIA)
EPS as of September 2026 TTM: $-1.32
According to Idorsia Ltd's latest financial reports, its current EPS (TTM) is $-1.32. At the end of 2025 the company had an EPS of $-0.66, an increase over its 2024 EPS of $-1.61.
EPS history for Idorsia Ltd from 2016 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-1.32 100.52%
2025 $-0.66 -59.18%
2024 $-1.61 -19.16%
2023 $-1.99 -60.69%
2022 $-5.05 22.15%
2021 $-4.14 19.06%
2020 $-3.47 -9.68%
2019 $-3.85 23.62%
2018 $-3.11 2,426.89%
2017 $-0.12 -95.54%
2016 $-2.76 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -32.75%
US
$15.66 -1,283.32%
US
$-7.07 434.23%
US
$-5.29 299.73%
AU
$12.73 -1,062.08%
BE

Questions about Idorsia Ltd's earnings per share (EPS)

What is Idorsia Ltd's earnings per share (EPS)?

Idorsia Ltd's earnings per share (EPS) over the last twelve months is $-1.32, as of Sep 2026.

What was Idorsia Ltd's earnings per share (EPS) in 2025?

In 2025, Idorsia Ltd's earnings per share (EPS) was $-0.66, compared with $-1.61 in 2024.

How has Idorsia Ltd's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Idorsia Ltd's earnings per share (EPS) was highest in 2025 ($-0.66) and lowest in 2022 ($-5.05).

How does Idorsia Ltd's earnings per share (EPS) compare with similar companies?

Idorsia Ltd's earnings per share (EPS) ($-1.32) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.